Eisai's Leqembi shows 76% lower progression rate to moderate or severe Alzheimer's in real-world study
BIIB•Eisai and Biogen presented three-year real-world findings showing a 76% lower progression rate to moderate or severe Alzheimer's dementia with Leqembi. The LEADER study covered 560 patients at 13 U.S. sites.
1. Three-year findings
Eisai and Biogen presented three-year real-world Leqembi findings at CTAD 2026. The LEADER study covered 560 patients across 13 U.S. sites; treated patients progressed more slowly to moderate or severe Alzheimer's dementia than a matched natural history cohort.
2. Patient and scan results
Most assessed patients remained stable or improved, and follow-up brain scans showed amyloid clearance in most patients evaluated. Weekly subcutaneous maintenance treatment showed continued disease stability, with no amyloid-related imaging abnormalities reported during that treatment period.
3. Separate safety analysis
A separate international analysis covering approximately 5,000 patients found lower rates of amyloid-related imaging abnormalities than the Clarity AD trial.



